Key facts
- This page summarizes Alan Colman's Form 4 filing for VOLITIONRX LTD (VNRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2022, 16:01.
Alan Colman - 23 Jun 2022 Form 4 Insider Report for VOLITIONRX LTD (VNRX)
- Reporting relationship
- Director
- Issuer ticker
- VNRX
- Reported as of
- 23 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2022, 16:01:23 UTC
- Prior SEC filing
- 08 Apr 2022
- Next SEC filing
- 14 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alan Colman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan Colman filed Form 4 for VOLITIONRX LTD (VNRX) on 24 Jun 2022.
Change
- Previous filing in this sequence was filed on 08 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VNRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,569
- Change %
- +2.9%
- Price
- $0.000000
- Shares after
- 163,279
- Date
- 23 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VNRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,420
- Change %
- +186%
- Price
- $0.000000
- Shares after
- 12,953
- Date
- 23 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,420
- Exercise price
- $3.40
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On August 3, 2021, the reporting person was awarded 7,029 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,569 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 2,285 units and 2,284 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 2,460 restricted stock units subject to the award previously vested and remain subject to time-based vesting.
Footnote F2
On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,420 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 4,211 shares and 4,209 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 4,533 shares subject to the award previously vested and remain subject to time-based vesting.